Fast Five Quiz: Myelodysplastic Syndrome Management

Emmanuel C. Besa, MD

Disclosures

May 12, 2021

Patients with MDS and increasing numbers of myeloblasts or disease progression to acute myelogenous leukemia should be treated with cytotoxic chemotherapy.

Hypomethylating agents, such as azacitidine, would be preferred in older patients who may not be able to tolerate chemotherapy. Lenalidomide has demonstrated good responses in patients with MDS and the 5q deletion. The use of antithymocyte globulin as immunosuppressive therapy remains experimental and has shown only limited effect in patients with MDS.

Learn more about the treatment of patients with MDS.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....